Hernández SJC, Mora FY, Abreu FN, Cardoso AE, Hernández RSM, Roque MM

Language: Spanish
References: 0
Page: 34-42
PDF size: 156.27 Kb.

ABSTRACT

Introduction: anemia is common in chronic kidney disease and is an independent predictor of cardiac morbidity and mortality in these patients.
Objective: to evaluate the benefits of the use of recombinant human erythropoietin in the treatment of renal anemia in patients with chronic predialytic renal failure.
Method: preexperiment was performed with pre and post test with a single group in the universe of chronic kidney patients in pre-dialysis stage (stages 3-4) with anemia of renal cause, attended at the General Provincial Teaching Hospital of Ciego de Ávila (67 patients). The study was carried out in the period from October 2014 to September 2015. It was limited to the four municipalities of the southern territory of the province. The Friedman test was used to search for association between variables of related samples.
Results: women between 60-79 years, hypertension and diabetes mellitus as causes predominated. The 91,0 % increased hemoglobin in the range 105-125 g/L and only 8,6 % maintained higher values. Chronic kidney disease did not progress and 49,0 % reduced the left ventricle mass index. The mean dose of EPOrHu administered was 4377 IU/week and did not vary significantly during the trial.
Conclusions: there was a significant increase in the mean values of hemoglobin and hematocrit after treatment with recombinant human erythropoietin. There were no changes in the disease, but there was improvement in left ventricular function, with an adequate haematological response with a weekly average dose less than 8000 IU/kg.